Literature DB >> 17395784

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity.

Chiara Borsotti1, Anna R K Franklin, Sydney X Lu, Theo D Kim, Odette M Smith, David Suh, Chris G King, Andrew Chow, Chen Liu, Onder Alpdogan, Marcel R M van den Brink.   

Abstract

Tumor necrosis factor (TNF) plays an important role in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) activity after allogeneic bone marrow transplantation (allo-BMT). TNF can be expressed in a membrane-bound form (memTNF) and as a soluble (solTNF) molecule after being cleaved by the TNF-alpha converting enzyme (TACE). To study the contribution of donor T-cell-derived memTNF versus solTNF in GVHD and GVT, we used mice containing a noncleavable allele in place of endogenous TNF (memTNF(Delta/Delta)) as donors in murine BMT models. Recipients of memTNF T cells developed significantly less GVHD than recipients of wild-type (wt) T cells. In contrast, GVT activity mediated by memTNF T cells remained intact, and alloreactive memTNF T cells showed no defects in proliferation, activation, and cytotoxicity. These data suggest that suppressing the secretion of solTNF by donor T cells significantly decreases GVHD without impairing GVT activity.

Entities:  

Mesh:

Year:  2007        PMID: 17395784      PMCID: PMC1924485          DOI: 10.1182/blood-2006-10-054510

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 2.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

3.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.

Authors:  M L Moss; S L Jin; M E Milla; D M Bickett; W Burkhart; H L Carter; W J Chen; W C Clay; J R Didsbury; D Hassler; C R Hoffman; T A Kost; M H Lambert; M A Leesnitzer; P McCauley; G McGeehan; J Mitchell; M Moyer; G Pahel; W Rocque; L K Overton; F Schoenen; T Seaton; J L Su; J D Becherer
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

4.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Authors:  R A Black; C T Rauch; C J Kozlosky; J J Peschon; J L Slack; M F Wolfson; B J Castner; K L Stocking; P Reddy; S Srinivasan; N Nelson; N Boiani; K A Schooley; M Gerhart; R Davis; J N Fitzner; R S Johnson; R J Paxton; C J March; D P Cerretti
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

5.  Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.

Authors:  K Hattori; T Hirano; H Miyajima; N Yamakawa; M Tateno; K Oshimi; N Kayagaki; H Yagita; K Okumura
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

6.  TNF receptor p55 controls early acute graft-versus-host disease.

Authors:  D E Speiser; M F Bachmann; T W Frick; K McKall-Faienza; E Griffiths; K Pfeffer; T W Mak; P S Ohashi
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

7.  Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.

Authors:  Cornelius Schmaltz; Onder Alpdogan; Stephanie J Muriglan; Barry J Kappel; Jimmy A Rotolo; Eric T Ricchetti; Andrew S Greenberg; Lucy M Willis; George F Murphy; James M Crawford; Marcel R M van den Brink
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

8.  Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells.

Authors:  W Krenger; S Rossi; L Piali; G A Holländer
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

9.  Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Authors:  S R Ruuls; R M Hoek; V N Ngo; T McNeil; L A Lucian; M J Janatpour; H Körner; H Scheerens; E M Hessel; J G Cyster; L M McEvoy; J D Sedgwick
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

10.  Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.

Authors:  Robert Korngold; Joseph C Marini; Monica E de Baca; George F Murphy; Jill Giles-Komar
Journal:  Biol Blood Marrow Transplant       Date:  2003-05       Impact factor: 5.742

View more
  12 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

Review 2.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

Review 3.  TNF activity and T cells.

Authors:  Amit K Mehta; Donald T Gracias; Michael Croft
Journal:  Cytokine       Date:  2016-08-13       Impact factor: 3.861

Review 4.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

5.  Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation.

Authors:  Antiopi Varelias; Kate H Gartlan; Ellen Kreijveld; Stuart D Olver; Mary Lor; Rachel D Kuns; Katie E Lineburg; Bianca E Teal; Neil C Raffelt; Melody Cheong; Kylie A Alexander; Motoko Koyama; Kate A Markey; Elise Sturgeon; Justine Leach; Pavan Reddy; Glen A Kennedy; Gregory A Yanik; Bruce R Blazar; Siok-Keen Tey; Andrew D Clouston; Kelli P A MacDonald; Kenneth R Cooke; Geoffrey R Hill
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

6.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

7.  Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.

Authors:  Tangsheng Yi; Dongchang Zhao; Chia-Lei Lin; Chunyan Zhang; Ying Chen; Ivan Todorov; Thomas LeBon; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-07-02       Impact factor: 22.113

8.  Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.

Authors:  Carrie L Kitko; Sophie Paczesny; Gregory Yanik; Thomas Braun; Dawn Jones; Joel Whitfield; Sung W Choi; Raymond J Hutchinson; James L M Ferrara; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

9.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

10.  Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Shin Mineishi; Thomas Braun; Sung W Choi; Raymond J Hutchinson; Dawn Jones; Yasser Khaled; Carrie L Kitko; Daniel Bickley; Oleg Krijanovski; Pavan Reddy; Gregory Yanik; James L M Ferrara
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.